ERBB2 and breast cancer: Although no standardized treatment strategies have been established for patients after first-line treatment with ERBB2-positive advanced breast cancer, many candidate third-line and beyond regimens were used historically, including lapatinib with capecitabine, trastuzumab with capecitabine, or other chemotherapeutics with continued trastuzumab (13, 28, 29).